Extremely good news. The study inferes "Data demonstrates potential of RECCE® 327 in new indications and to form part of a broader anti-infective treatment model in pre-sepsis" which is absolute gold because no longer is Recce 327 an intermittently consumed drug. For many it may form a broader anti sepsis protocol as the drug appears to not create disease-resistant bacteria.
The broader treatment model may not necessarily be via the oral route. Personally, I think the RECCE327 could have a role in impregnated Indwelling urinary catheters including SPC. Catheter-associated urinary tract infection (CAUTI) accounts for up to 80% of indwelling urinary catheter usage rate. Cruching some numbers, 10% of nursing home patients in the USA are catheterised, A recent Australian study found about 26% of acute care patients had a catheter inserted while on admission. Basically what I am trying to get at is the market for RECCE327 is enormous now that the company is thinking outside of acute treatment.
This is really great great news for the long journey ahead.
RCE Price at posting:
46.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)